Last reviewed · How we verify
Atropine sulfate eye drops 0.02%
Atropine blocks muscarinic acetylcholine receptors in the eye to dilate the pupil and paralyze accommodation, slowing myopia progression in children.
Atropine blocks muscarinic acetylcholine receptors in the eye to dilate the pupil and paralyze accommodation, slowing myopia progression in children. Used for Myopia progression control in children (Phase 3).
At a glance
| Generic name | Atropine sulfate eye drops 0.02% |
|---|---|
| Sponsor | Oupushifang Pharmaceutical Technology Co., Ltd. |
| Drug class | Anticholinergic agent / Muscarinic receptor antagonist |
| Target | Muscarinic acetylcholine receptors (M1-M5, primarily M1 and M3) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Atropine is an anticholinergic agent that competitively antagonizes muscarinic receptors on the ciliary muscle and iris sphincter muscle. By blocking acetylcholine signaling, it prevents accommodation (lens thickening) and causes mydriasis (pupil dilation). In pediatric myopia, low-dose atropine is thought to work through multiple mechanisms including reduced accommodation-induced axial elongation and potential direct effects on scleral remodeling.
Approved indications
- Myopia progression control in children (Phase 3)
Common side effects
- Mydriasis (pupil dilation)
- Cycloplegia (accommodation paralysis)
- Photophobia (light sensitivity)
- Blurred vision
- Ocular irritation or discomfort
Key clinical trials
- Atropine (0.02%, 0.04%) Combined With Defocus DIMS for Moderate and High Myopia Control (PHASE1, PHASE2)
- Low-dose Atropine for Myopia Control in Children (PHASE2, PHASE3)
- The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Pediatric Myopia Progression (PHASE3)
- Low Concentration Atropine in the Prevention of Myopia in Children. (NA)
- Evaluation of Short Term Use of Experimental Eye Drops BHVI2, 0.02% Atropine and BHVI2 Plus 0.02% Atropine Eye Drops (PHASE1)
- Effects of Low Concentration Atropine on Pupillary Size and Accommodative Amplitude (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: